Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir-based prophylaxis after liver transplantation for hepatitis B
2008-005976-28Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- Apr 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of entecavir, tenofovir disoproxil fumarate and hepatitis B immune globulin in hepatitis B (HBV) (2 arms), sponsored by Hannover Medical School. Primary endpoints: HBsAg status 12 months after liver transplantation and HBsAg negativity in the second year after liver transplantation. Started Apr 2009; status: completed.
02
Drugs
entecavirtenofovir disoproxil fumaratehepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2008-005976-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005976-28.